Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10381205 | 0.88 | MAOB (0.71) | MAOBL3MBTL1MAOAALDH1A1LMNA | |
| SCHEMBL5259021 | 0.81 | MAOB (0.81) | MAOBMAPTRAB9AMAOAALDH1A1 | |
| SCHEMBL22230050 | 0.81 | BRD4 (0.51) | MAPTL3MBTL1ALDH1A1LMNAKDM4E | |
| SCHEMBL5160401 | 0.80 | MAOB (0.50) | MAOBNPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL19309822 | 0.80 | RAB9A (0.50) | MAOBNPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1299217 | 0.79 | MAOB (0.58) | MAOBNPC1MAPTRAB9AMAOA | |
| SCHEMBL8761733 | 0.79 | MAOB (0.61) | MAOBNPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL22386473 | 0.79 | KDM4E (0.49) | MAOBNPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL1919254 | 0.79 | MAPT (0.58) | MAOBNPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL23984753 | 0.78 | MAPT (0.54) | MAOBNPC1MAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260123269-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-20200216434-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2020-07-09 | — | — | US | disclosed |
| EP-3638662-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | European Molecular Biology Laboratory (DE) | 2020-04-22 | — | — | EP | disclosed |
| CN-110997663-A | Benzofuran ureas or carbamates and heteroaromatic analogs thereof for use in therapy | 欧洲分子生物学实验室 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018229194-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2018-12-20 | — | — | WO | disclosed |
| CN-106986862-A | Hepatitis c inhibitor and application thereof | ABBVIE 公司 | 2017-07-28 | — | — | CN | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-6552071-B2 | Wedelolactone and its synthesis for treating neurodegenerative diseases | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-04-22 | — | — | US | disclosed |
| EP-1237550-A2 | METHODS FOR TREATING CELL DEATH DISEASES AND INFLAMMATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020049251-A1 | Methods for treating cell death diseases and inflammation | HARVARD COLLEGE, PRESIDENT AND FELLOWS | 2002-04-25 | — | — | US | disclosed |
| WO-2001041709-A2 | METHODS FOR TREATING CELL DEATH DISEASES AND INFLAMMATION | PRESIDENT AND FELLOWS OF HARWARD COLLEGE (US) | 2001-06-14 | — | — | WO | disclosed |
| US-5859007-A | TREATMENT OF DIABETES, OBESITY | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5665722-A | Benzofuran derivatives as D4 receptor antagonists | MERCK, SHARP & DOHME, LTD. (GB) | 1997-09-09 | — | — | US | disclosed |
| EP-0757686-A1 | BENZOFURAN DERIVATIVES AS D 4? RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1997-02-12 | — | — | EP | disclosed |
| EP-0755384-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995029911-A1 | BENZOFURAN DERIVATIVES AS D4 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995028391-A1 | CCK OR GASTRIN MODULATING 1,5 BENZODIAZEPINES DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260123269-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, LDLR, MLX | MAOB 388/4885NPC1 1369/4885MAPT 3924/4885 |
| US-20020049251-A1 | Methods for treating cell death diseases and inflammation | CASP3, CASP9, CASP2 | MAOB 4132/4885NPC1 379/4885MAPT 1132/4885 |
| US-20200216434-A1 | BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY | NR0B1, NR4A3, NR0B2 | MAOB 1128/4885NPC1 2640/4885MAPT 2496/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | MAOB 4108/4885NPC1 3314/4885MAPT 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.